Initial clinical experience with N-hexyl cyanoacrylate for neuroendovascular embolization

Objective To report our initial clinical experience with N-hexyl cyanoacrylate (NHCA), a novel liquid agent for neurovascular embolization. Methods Four paragangliomas were treated with percutaneous embolization using NHCA as the sole embolic material. In one dural arteriovenous fistula (dAVF), NHCA was used in combination with other embolic materials. Procedural specifics, complications and angiographic results were retrospectively evaluated. Results Total or subtotal devascularization was obtained in 3 of the 4 paragangliomas. In the largest tumor, only partial devascularization could be achieved. The dAVF was completely occluded. Catheter entrapment did not occur. After dAVF treatment, the patient had an asymptomatic lacunar infarction, while there was no procedural morbidity related to paraganglioma treatment. Conclusions In this series, neurovascular embolization with NHCA was feasible and effective. It may be particularly beneficial for small and tortuous vessels that require low-profile catheterization and a slow and controlled polymerization. Further studies are necessary to prove the benefits of NHCA over established embolic agents.

Automated summary

This study reports the initial clinical experience with NHCA as a liquid embolic agent for neurovascular embolization. The results show that NHCA is feasible and effective, particularly for small and tortuous vessels that require low-profile catheterization and a slow and controlled polymerization. Further studies are needed to prove the benefits of NHCA over established embolic agents.